Skip to main content

Clinical Neuroimmunology

The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches. 

Team

Alarcon Gimenez, Irene

Alarcon Gimenez, Irene

Clinical Neuroimmunology
Read more
Andres Miguez Gonzalez

Andres Miguez Gonzalez

Main researcher
Clinical Neuroimmunology
Read more
Andreu Vilaseca Jolonch

Andreu Vilaseca Jolonch

Predoctoral researcher
Clinical Neuroimmunology
Read more
Ariño  Rodríguez, Helena

Ariño Rodríguez, Helena

Postdoctoral researcher
Clinical Neuroimmunology
Read more
Arnau Hervera Abad

Arnau Hervera Abad

Main researcher
Clinical Neuroimmunology
Read more
Aroca Alsina, Montserrat

Aroca Alsina, Montserrat

Research assistant
Clinical Neuroimmunology
Read more
Alarcon Gimenez, Irene

Alarcon Gimenez, Irene

Clinical Neuroimmunology
Read more
Andres Miguez Gonzalez

Andres Miguez Gonzalez

Main researcher
Clinical Neuroimmunology
Read more
Andreu Vilaseca Jolonch

Andreu Vilaseca Jolonch

Predoctoral researcher
Clinical Neuroimmunology
Read more
Ariño  Rodríguez, Helena

Ariño Rodríguez, Helena

Postdoctoral researcher
Clinical Neuroimmunology
Read more
Arnau Hervera Abad

Arnau Hervera Abad

Main researcher
Clinical Neuroimmunology
Read more
Aroca Alsina, Montserrat

Aroca Alsina, Montserrat

Research assistant
Clinical Neuroimmunology
Read more

Projects

BEHIND-MS: The role of an Epstein-Barr virus infection in the pathogenesis of multiple sclerosis

IP: Manuel Comabella Lopez
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 248720
Reference: BEHIND-MS_HE-HLTH2023
Duration: 01/12/2023 - 30/11/2028

Red de investigación en inflammasoma y piroptosis en enfermedades crónicas y cáncer

IP: Manuel Comabella Lopez
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: RED2022-134511-T
Duration: 01/06/2023 - 31/05/2025

Ministerio de Ciencia

Beca VHIR PhD

IP: Manuel Comabella Lopez
Collaborators: Beca VHIR PhD, Laia Perez Lasarte, Elisa Marín Ordovás, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 69188.74
Reference: VPHD/ELISA_M
Duration: 01/04/2023 - 31/03/2026

x

IP: Xavier Montalban Gairín
Collaborators: Arnau Hervera Abad, Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 236350
Reference: RYC2021-033528-I
Duration: 01/01/2023 - 31/12/2027

Ministerio de Ciencia

Publications

Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.

PMID: 39819099
Journal: NEUROLOGY
Year: 2025
Reference: Neurology. 2025 Feb 11;104(3):e210281. doi: 10.1212/WNL.0000000000210281. Epub 2025 Jan 16.
Impact factor:
Publication type: Paper in international publication
Authors: Borras-Bermejo, Blanca; Carbonell-Mirabent, Pere; Carvajal, Rene; Cobo-Calvo, Alvaro; Esperalba, Juliana; Guananga-Alvarez, David; Martinez-Gomez, Xavier; Montalban, Xavier; Otero-Romero, Susana; Rando-Segura, Ariadna et al.
DOI: 10.1212/WNL.0000000000210281

Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis.

PMID: 39879564
Journal: Neurology-Neuroimmunology & Neuroinflammation
Year: 2025
Reference: Neurol Neuroimmunol Neuroinflamm. 2025 Mar;12(2):e200370. doi: 10.1212/NXI.0000000000200370. Epub 2025 Jan 29.
Impact factor:
Publication type: Paper in international publication
Authors: Arino, Helena; Arrambide, Georgina; Auger, Cristina; Bollo, Luca; Carbonell-Mirabent, Pere; Carvajal, Rene; Castillo, Joaquin; Cobo-Calvo, Alvaro; Comabella, Manuel; Costa Frossard, Lucienne F et al.
DOI: 10.1212/NXI.0000000000200370

Age-Related Disability Outcomes After a First Demyelinating Event.

PMID: 39903901
Journal: NEUROLOGY
Year: 2025
Reference: Neurology. 2025 Feb 25;104(4):e210305. doi: 10.1212/WNL.0000000000210305. Epub 2025 Feb 4.
Impact factor:
Publication type: Paper in international publication
Authors: Arevalo Navines, Maria Jesus; Arino, Helena; Arrambide, Georgina; Auger, Cristina; Bollo, Luca; Carbonell-Mirabent, Pere; Carvajal, Rene; Castillo, Joaquin; Cobo-Calvo, Alvaro; Comabella, Manuel et al.
DOI: 10.1212/WNL.0000000000210305

Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of Immunosenescence.

PMID: 39894902
Journal: AGING CELL
Year: 2025
Reference: Aging Cell. 2025 Feb 2:e14491. doi: 10.1111/acel.14491.
Impact factor:
Publication type: Paper in international publication
Authors: Castillo, Mireia; Dema, Maria; Eixarch, Herena; Espejo, Carmen; Hervera, Arnau; Montalban, Xavier; Villar, Luisa M et al.
DOI: 10.1111/acel.14491

Priority setting: women's health topics in multiple sclerosis.

PMID: 38440114
Journal: Frontiers in Neurology
Year: 2024
Reference: Front Neurol. 2024 Feb 19;15:1355817. doi: 10.3389/fneur.2024.1355817. eCollection 2024.
Impact factor:
Publication type: Paper in international publication
Authors: Amato, Maria Pia; Cohen, Jeffrey Alan; Finlayson, Marcia; Hellwig, Kerstin; Marrie, Ruth Ann; Ross, Lindsay; Salter, Amber; Tintore, Mar; Vukusic, Sandra et al.
DOI: 10.3389/fneur.2024.1355817

Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

PMID: 38447105
Journal: NEUROLOGY
Year: 2024
Reference: Neurology. 2024 Apr 9;102(7):e209156. doi: 10.1212/WNL.0000000000209156. Epub 2024 Mar 6.
Impact factor:
Publication type: Paper in international publication
Authors: Acevedo, Breogan Rodriguez; Alberich, Manel; Alvarez, Javier V; Arrambide, Georgina; Auger, Cristina; Bollo, Luca; Cabello, Sergio; Castillo, Joaquin; Cobo-Calvo, Alvaro; Comabella, Manuel et al.
DOI: 10.1212/WNL.0000000000209156

An emerging etiology of spinal cord injury resembling neuromyelitis optica spectrum disorder.

PMID: 38483675
Journal: NEUROLOGICAL SCIENCES
Year: 2024
Reference: Neurol Sci. 2024 Mar 14. doi: 10.1007/s10072-024-07464-1.
Impact factor:
Publication type: Other (letters to the editor, abstracts, corrigendum, etc.)
Authors: Auger, Cristina; de Gordoa, Estibaliz Saez; Girame-Rizzo, Lidia; Montalban, Xavier; Vilaseca, Andreu et al.
DOI: 10.1007/s10072-024-07464-1

Safety and efficacy of early carotid artery stenting in patients with symptomatic stenosis.

PMID: 38515363
Journal: INTERVENTIONAL NEURORADIOLOGY
Year: 2024
Reference: Interv Neuroradiol. 2024 Mar 22:15910199241239204. doi: 10.1177/15910199241239204.
Impact factor:
Publication type: Paper in international publication
Authors: De Dios, Marta; Diana, Francesco; Elosua, Iker; Garcia-Tornel, Alvaro; Gramegna, Laura Ludovica; Hernandez, David; Juega, Jesus; Mayol, Jordi; Molina, Carlos; Muchada, Marian et al.
DOI: 10.1177/15910199241239204

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.

PMID: 36534274
Journal: Neurology and Therapy
Year: 2023
Reference: Neurol Ther. 2023 Feb;12(1):303-317. doi: 10.1007/s40120-022-00427-8. Epub 2022 Dec 19.
Impact factor:
Publication type: Paper in international publication
Authors: Bagger, Morten; Bar-Or, Amit; Coello, Neva; Fox, Edward; Haring, Dieter A; Hu, Xixi; Kieseier, Bernd C; Kropshofer, Harald; Kukkaro, Petra; Ludwig, Inga et al.
DOI: 10.1007/s40120-022-00427-8

Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement.

PMID: 36527368
Journal: Multiple Sclerosis Journal
Year: 2023
Reference: Mult Scler. 2023 Feb;29(2):182-195. doi: 10.1177/13524585221134217. Epub 2022 Dec 17.
Impact factor:
Publication type: Paper in international publication
Authors: Arrambide, Georgina; Deisenhammer, Florian; Gnanapavan, Sharmilee; Hegen, Harald; Kaplan, Batia; Khalil, Michael; Saadeh, Ruba; Teunissen, Charlotte; Tumani, Hayrettin; Villar, Luisa Maria et al.
DOI: 10.1177/13524585221134217

Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.

PMID: 36526426
Journal: NEUROLOGY
Year: 2023
Reference: Neurology. 2023 Mar 14;100(11):e1095-e1108. doi: 10.1212/WNL.0000000000201662. Epub 2022 Dec 16.
Impact factor:
Publication type: Paper in international publication
Authors: Armangue, Thais; Arrambide, Georgina; Ayzenberg, Ilya; Baumann, Matthias; Bernard-Valnet, Raphael; Breu, Markus; Brilot, Fabienne; CartaAlvaro Cobo Calvo, Sara; Du Pasquier, Renaud A; Ferrari, Sergio et al.
DOI: 10.1212/WNL.0000000000201662

Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.

PMID: 36515487
Journal: Multiple Sclerosis Journal
Year: 2023
Reference: Mult Scler. 2023 Mar;29(3):352-362. doi: 10.1177/13524585221141964. Epub 2022 Dec 14.
Impact factor:
Publication type: Paper in international publication
Authors: Alberich, Manel; Barkhof, Frederik; Calvi, Alberto; Chard, Declan; Ciccarelli, Olga; Clarke, Margareta A; Pareto, Deborah; Prados, Ferran; Rodriguez Barranco, Marta; Rovira, Alex et al.
DOI: 10.1177/13524585221141964

Gadolinium-enhanced brain lesions in multiple sclerosis relapse.

PMID: 36064284
Journal: NEUROLOGIA
Year: 2022
Reference: Neurologia (Engl Ed). 2022 Sep;37(7):557-563. doi: 10.1016/j.nrleng.2021.10.005.
Impact factor:
Publication type: Paper in international publication
Authors: Batlle-Nadal, J; Blanco, Y; Brieva-Ruiz, L; Cano-Orgaz, A; Capellades, J; Carmona, O; Gea, M; Hervas-Garcia, J V; Martin-Aguilar, L; Massuet-Vilamajo, A et al.
DOI: 10.1016/j.nrleng.2021.10.005

Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.

PMID: 36038263
Journal: Neurology-Neuroimmunology & Neuroinflammation
Year: 2022
Reference: Neurol Neuroimmunol Neuroinflamm. 2022 Aug 29;9(6). pii: 9/6/e200021. doi: 10.1212/NXI.0000000000200021. Print 2022 Nov.
Impact factor:
Publication type: Paper in international publication
Authors: Alonso, Ricardo N; Alroughani, Raed; Arrambide, Georgina; Bebo, Bruce; Bergmann, Arnfin B; Boz, Cavit; Braune, Stefan; Butzkueven, Helmut; Chertcoff, Anibal S; Comi, Giancarlo et al.
DOI: 10.1212/NXI.0000000000200021

Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.

PMID: 36017870
Journal: Multiple Sclerosis Journal
Year: 2022
Reference: Mult Scler. 2022 Dec;28(14):2212-2220. doi: 10.1177/13524585221118677. Epub 2022 Aug 26.
Impact factor:
Publication type: Review in international publication
Authors: Allen, Christopher Martin; Altokhis, Amjad; Calabrese, Massimiliano; Clarke, Margareta A; De Stefano, Nicola; Enzinger, Christian; Evangelou, Nikos; Giorgio, Antonio; Granziera, Cristina; Kappos, Ludwig et al.
DOI: 10.1177/13524585221118677

Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.

PMID: 36000489
Journal: Multiple Sclerosis Journal
Year: 2022
Reference: Mult Scler. 2022 Dec;28(14):2177-2189. doi: 10.1177/13524585221116269. Epub 2022 Aug 24.
Impact factor:
Publication type: Paper in international publication
Authors: Anshasi, Nadia; Bobrovnikova, Olga; Brownlee, Wallace J; Clark, Richard Ac; Cohen, Jeffrey A; Dallmann, Gabriele; Dingermann, Theo; Hartung, Hans-Peter; Selmaj, Krzysztof; Sintzel, Martina et al.
DOI: 10.1177/13524585221116269

Genetic variation in NDFIP1 modifies the metabolic patterns in immune cells of multiple sclerosis patients.

PMID: 34725369
Journal: Scientific Reports
Year: 2021
Reference: Sci Rep. 2021 Nov 1;11(1):21371. doi: 10.1038/s41598-021-00528-8.
Impact factor:
Publication type: Paper in international publication
Authors: Abarca-Zabalia, Judith; Agudo-Jimenez, Teresa; Aladro, Yolanda; Comabella, Manuel; Espino-Paisan, Laura; Gonzalez-Jimenez, Adela; Lopez-Cotarelo, Pilar; Pilo, Belen; Urcelay, Elena et al.
DOI: 10.1038/s41598-021-00528-8

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab.

PMID: 34691084
Journal: Frontiers in Immunology
Year: 2021
Reference: Front Immunol. 2021 Oct 8;12:760546. doi: 10.3389/fimmu.2021.760546. eCollection 2021.
Impact factor:
Publication type: Paper in international publication
Authors: Alvarez-Lafuente, Roberto; Carrasco-Sayalero, Angela; Comabella, Manuel; Costa-Frossard, Lucienne; Fernandez-Velasco, Jose Ignacio; Lapuente, Paloma; Masjuan, Jaime; Meca-Lallana, Jose; Medina, Silvia; Midaglia, Luciana et al.
DOI: 10.3389/fimmu.2021.760546

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

PMID: 34644366
Journal: PLoS One
Year: 2021
Reference: PLoS One. 2021 Oct 13;16(10):e0258437. doi: 10.1371/journal.pone.0258437. eCollection 2021.
Impact factor:
Publication type: Paper in international publication
Authors: Alvarez-Cermeno, J C; Fernandez, O; Hernandez, M A; Marzo, M E; Meca-Lallana, J E; Meca-Lallana, V; Montalban, X; Munoz, D; Olascoaga, J; Oreja-Guevara, C et al.
DOI: 10.1371/journal.pone.0258437

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis.

PMID: 34630632
Journal: Therapeutic Advances in Neurological Disorders
Year: 2021
Reference: Ther Adv Neurol Disord. 2021 Oct 5;14:17562864211031099. doi: 10.1177/17562864211031099. eCollection 2021.
Impact factor:
Publication type: Paper in international publication
Authors: Caruso, Diego; Drzewiscki, Estefania; Esnaola Y Rojas, Maria M; Smietniansky, Maximiliano; Tagliani, Paula; Zanga, Gisela et al.
DOI: 10.1177/17562864211031099

Palliative care in multiple sclerosis: European guideline.

PMID: 32513039
Journal: Multiple Sclerosis Journal
Year: 2020
Reference: Mult Scler. 2020 Aug;26(9):1009-1011. doi: 10.1177/1352458520926467. Epub 2020 Jun 9.
Impact factor:
Publication type: Paper in international publication
Authors: Aleksovska, Katina; Battaglia, Mario A; Bay, Jette; Copetti, Massimiliano; Drulovic, Jelena; Giordano, Andrea; Kleiter, Ingo; Kooij, Liesbeth; Kopke, Sascha; Mens, John et al.
DOI: 10.1177/1352458520926467

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.

PMID: 33129442
Journal: LANCET NEUROLOGY
Year: 2020
Reference: Lancet Neurol. 2020 Dec;19(12):998-1009. doi: 10.1016/S1474-4422(20)30342-2. Epub 2020 Oct 29.
Impact factor:
Publication type: Paper in international publication
Authors: Arnold, Douglas L; Bennett, Iain; Brochet, Bruno; Hartung, Hans-Peter; Hauser, Stephen L; Hubeaux, Stanislas; Kappos, Ludwig; Koendgen, Harold; Manfrini, Marianna; Montalban, Xavier et al.
DOI: 10.1016/S1474-4422(20)30342-2

Modelling multiple sclerosis using induced pluripotent stem cells.

PMID: 33130461
Journal: JOURNAL OF NEUROIMMUNOLOGY
Year: 2020
Reference: J Neuroimmunol. 2020 Dec 15;349:577425. doi: 10.1016/j.jneuroim.2020.577425. Epub 2020 Oct 17.
Impact factor:
Publication type: Review in international publication
Authors: Comabella, Manuel; Martinez-Larrosa, Julia; Matute-Blanch, Clara; Montalban, Xavier et al.
DOI: 10.1016/j.jneuroim.2020.577425

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.

PMID: 33125391
Journal: PLOS MEDICINE
Year: 2020
Reference: PLoS Med. 2020 Oct 30;17(10):e1003348. doi: 10.1371/journal.pmed.1003348. eCollection 2020 Oct.
Impact factor:
Publication type: Paper in international publication
Authors: Aktas, Orhan; Allez, Matthieu; Auer, Michael; Avouac, Jerome; Bachelet, Delphine; Birchler, Mary; Bouhnik, Yoram; Brocq, Olivier; Broet, Philippe; Buck-Martin, Dorothea et al.
DOI: 10.1371/journal.pmed.1003348

Head-to-head drug comparisons in multiple sclerosis: Urgent action needed.

PMID: 31591277
Journal: NEUROLOGY
Year: 2019
Reference: Neurology. 2019 Oct 29;93(18):793-809. doi: 10.1212/WNL.0000000000008319. Epub 2019 Oct 7.
Impact factor:
Publication type: Review in international publication
Authors: Butzkueven, Helmut; Kalincik, Tomas; Montalban, Xavier; Oh, Jiwon; Sormani, Maria P; Tintore, Mar; Tur, Carmen et al.
DOI: 10.1212/WNL.0000000000008319

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.

PMID: 31604244
Journal: SCIENCE
Year: 2019
Reference: Science. 2019 Sep 27;365(6460). pii: 365/6460/eaav7188. doi: 10.1126/science.aav7188.
Impact factor:
Publication type: Paper in international publication
Authors: Agliardi, Cristina; Alfredsson, Lars; Amoroso, Antonio; An, David; Andlauer, Till F M; Baker, Amie; Ban, Maria; Baranzini, Sergio E; Barcellos, Lisa F; Barizzone, Nadia et al.
DOI: 10.1126/science.aav7188

Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study.

PMID: 31596725
Journal: JOURNAL OF MEDICAL INTERNET RESEARCH
Year: 2019
Reference: J Med Internet Res. 2019 Oct 8;21(10):e16287. doi: 10.2196/16287.
Impact factor:
Publication type: Letter or abstract
Authors: Baker, Michael; Belachew, Shibeshih; Bernasconi, Corrado; Gossens, Christian; Graves, Jennifer; Hauser, Stephen L; Julian, Laura; Lindemann, Michael; Lipsmeier, Florian; Midaglia, Luciana et al.
DOI: 10.2196/16287

Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.

PMID: 29985092
Journal: Multiple Sclerosis Journal
Year: 2019
Reference: Mult Scler. 2019 Oct;25(11):1535-1538. doi: 10.1177/1352458518786055. Epub 2018 Jul 9.
Impact factor:
Publication type: Paper in international publication
Authors: Alvarez-Cermeno, Jose Carlos; Cervera-Carles, Laura; Clarimon, Jordi; Comabella, Manuel; Drulovic, Jelena; Dujmovic, Irena; Fissolo, Nicolas; Gil, Elia; Khalil, Michael; Lleo, Alberto et al.
DOI: 10.1177/1352458518786055

Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis.

PMID: 30480030
Journal: Annals of Clinical and Translational Neurology
Year: 2018
Reference: Ann Clin Transl Neurol. 2018 Sep 23;5(11):1362-1371. doi: 10.1002/acn3.646. eCollection 2018 Nov.
Impact factor:
Publication type: Paper in international publication
Authors: Amezcua, Lilyana; Beecham, Ashley H; Burnett, Margaret; Chinea, Angel; Comabella, Manuel; Conti, David; Delgado, Silvia R; Gomez, Refujia; Islam, Talat; Lund, Brett T et al.
DOI: 10.1002/acn3.646

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.

PMID: 30415593
Journal: Multiple Sclerosis Journal
Year: 2018
Reference: Mult Scler. 2018 Dec;24(14):1862-1870. doi: 10.1177/1352458518808189. Epub 2018 Nov 12.
Impact factor:
Publication type: Paper in international publication
Authors: Applebee, Angela; Belachew, Shibeshih; Fiore, Damian; Fox, Edward J; Giovannoni, Gavin; Markowitz, Clyde; Montalban, Xavier; Musch, Bruno; Pei, Jinglan; Wolinsky, Jerry S et al.
DOI: 10.1177/1352458518808189

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

PMID: 30367633
Journal: Journal of Neuroinflammation
Year: 2018
Reference: J Neuroinflammation. 2018 Oct 26;15(1):296. doi: 10.1186/s12974-018-1336-9.
Impact factor:
Publication type: Paper in international publication
Authors: Alvarez-Cermeno, Jose C; Castillo, Joaquin; Comabella, Manuel; Costa, Carme; Cubedo, Marta; Fissolo, Nicolas; Malhotra, Sunny; Medina, Silvia; Midaglia, Luciana; Montalban, Xavier et al.
DOI: 10.1186/s12974-018-1336-9

Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists.

PMID: 30319523
Journal: Frontiers in Neurology
Year: 2018
Reference: Front Neurol. 2018 Sep 24;9:781. doi: 10.3389/fneur.2018.00781. eCollection 2018.
Impact factor:
Publication type: Paper in international publication
Authors: Bakdache, Fabien; Caceres, Fernando; Fruns, Manuel; Montalban, Xavier; Montoya, Alonso; Oh, Jiwon; Saposnik, Gustavo; Selchen, Daniel; Terzaghi, Maria A et al.
DOI: 10.3389/fneur.2018.00781

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

PMID: 27354019
Journal: Multiple Sclerosis Journal
Year: 2017
Reference: Mult Scler. 2017 Apr;23(4):556-566. doi: 10.1177/1352458516656808. Epub 2016 Jul 11.
Impact factor:
Publication type: Paper in international publication
Authors: Auger, Cristina; Ciampi, Ethel; Montalban, Xavier; Pareto, Deborah; Rio, Jordi; Rovira, Alex; Sastre-Garriga, Jaume; Tintore, Mar; Tur, Carmen; Vidal-Jordana, Angela et al.
DOI: 10.1177/1352458516656808

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.

PMID: 27001119
Journal: PHARMACOGENOMICS JOURNAL
Year: 2017
Reference: Pharmacogenomics J. 2017 Jul;17(4):312-318. doi: 10.1038/tpj.2016.20. Epub 2016 Mar 22.
Impact factor:
Publication type: Paper in international publication
Authors: Antiguedad, A; Boneschi, F M; Clarelli, F; Comabella, M; Comi, G; Fabis-Pedrini, M J; Gatt, P N; Jokubaitis, V G; Kermode, A G; King, C et al.
DOI: 10.1038/tpj.2016.20

Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system.

PMID: 29110780
Journal: Handbook of clinical neurology
Year: 2017
Reference: Handb Clin Neurol. 2017;146:67-84. doi: 10.1016/B978-0-12-804279-3.00005-8.
Impact factor:
Publication type: Review in international publication
Authors: Comabella, Manuel; Matute-Blanch, Clara; Montalban, Xavier et al.
DOI: 10.1016/B978-0-12-804279-3.00005-8

Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

PMID: 29101276
Journal: NEUROLOGY
Year: 2017
Reference: Neurology. 2017 Dec 5;89(23):2351-2356. doi: 10.1212/WNL.0000000000004715. Epub 2017 Nov 3.
Impact factor:
Publication type: Paper in international publication
Authors: Arrambide, Georgina; Auger, Cristina; Castillo, Joaquin; Comabella, Manuel; de Barros, Andrea; Galan, Ingrid; Midaglia, Luciana; Mitjana, Raquel; Montalban, Xavier; Mulero, Patricia et al.
DOI: 10.1212/WNL.0000000000004715

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.

PMID: 26111826
Journal: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Year: 2016
Reference: J Neurol Neurosurg Psychiatry. 2016 May;87(5):468-75. doi: 10.1136/jnnp-2015-310597. Epub 2015 Jun 25.
Impact factor:
Publication type: Paper in international publication
Authors: Barkhof, Frederik; Cohen, Jeffrey A; Comi, Giancarlo; Hartung, Hans-Peter; Kappos, Ludwig; Khatri, Bhupendra; Montalban, Xavier; Pelletier, Jean; Ritter, Shannon; Stites, Tracy et al.
DOI: 10.1136/jnnp-2015-310597

Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.

PMID: 26432859
Journal: Multiple Sclerosis Journal
Year: 2016
Reference: Mult Scler. 2016 Jun;22(7):901-9. doi: 10.1177/1352458515607650. Epub 2015 Oct 2.
Impact factor:
Publication type: Paper in international publication
Authors: Barkhof, F; Ciccarelli, O; Damjanovic, D; de Stefano, N; Enzinger, C; Filippi, M; Gallo, A; Hulst, H E; Montalban, X; Rocca, M A et al.
DOI: 10.1177/1352458515607650

Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study.

PMID: 26833969
Journal: HUMAN BRAIN MAPPING
Year: 2016
Reference: Hum Brain Mapp. 2016 Apr;37(4):1627-44. doi: 10.1002/hbm.23125. Epub 2016 Feb 2.
Impact factor:
Publication type: Paper in international publication
Authors: Arevalo, Maria J; Atzori, Matteo; Barkhof, Frederik; Bisecco, Alvino; Copetti, Massimiliano; De Stefano, Nicola; Enzinger, Christian; Fazekas, Franz; Filippi, Massimo; Gallo, Antonio et al.
DOI: 10.1002/hbm.23125

MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.

PMID: 26604134
Journal: HUMAN MOLECULAR GENETICS
Year: 2016
Reference: Hum Mol Genet. 2016 Jan 15;25(2):308-16. doi: 10.1093/hmg/ddv473. Epub 2015 Nov 24.
Impact factor:
Publication type: Paper in international publication
Authors: Auger, Cristina; Aymerich, Xavier; Canto, Ester; Castillo, Joaquin; Comabella, Manuel; Fissolo, Nicolas; Montalban, Xavier; Nurtdinov, Ramil; Picon, Carmen; Rio, Jordi et al.
DOI: 10.1093/hmg/ddv473

Significant clinical worsening after natalizumab withdrawal: Predictive factors.

PMID: 25392320
Journal: MULT SCLER J
Year: 2015
Reference: Mult Scler. 2015 May;21(6):780-5. doi: 10.1177/1352458514549401. Epub 2014 Nov 12.
Impact factor:
Publication type: Paper in international publication
Authors: Arrambide, G; Auger, C; Castillo, J; Comabella, M; Galan, I; Montalban, X; Nos, C; Perez-Miralles, F; Rio, J; Rovira, A et al.
DOI: 10.1177/1352458514549401

Brain atrophy in natalizumab-treated patients: A 3-year follow-up.

PMID: 25392330
Journal: MULT SCLER J
Year: 2015
Reference: Mult Scler. 2015 May;21(6):749-56. doi: 10.1177/1352458514556300. Epub 2014 Nov 12.
Impact factor:
Publication type: Paper in international publication
Authors: Auger, C; Huerga, E; Montalban, X; Pareto, D; Rio, J; Rovira, A; Sastre-Garriga, J; Tintore, M; Tur, C; Vidal-Jordana, A et al.
DOI: 10.1177/1352458514556300

Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses.

PMID: 25145693
Journal: MULT SCLER J
Year: 2015
Reference: Mult Scler. 2015 Apr;21(5):646-50. doi: 10.1177/1352458514546786. Epub 2014 Aug 21.
Impact factor:
Publication type: Paper in international publication
Authors: Brieva, L; Cano, A; Carmona, O; Grau-Lopez, L; Hervas, J V; Martinez-Caceres, E M; Ramio-Torrenta, L; Ramo-Tello, C; Rovira, A; Saiz, A et al.
DOI: 10.1177/1352458514546786

Reproducibility of qualitative assessments of temporal lobe atrophy in MRI studies.

PMID: 24970598
Journal: Radiologia
Year: 2015
Reference: Radiologia. 2015 May-Jun;57(3):225-8. doi: 10.1016/j.rx.2014.04.002. Epub 2014 Jun 23.
Impact factor:
Publication type: Letter or abstract
Authors: Acevedo, C; Auger, C; Frascheri, L; Mitjana, R; Rovira, A; Sarria-Estrada, S; Siurana, S et al.
DOI: 10.1016/j.rx.2014.04.002

Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study.

PMID: 25045065
Journal: HUMAN BRAIN MAPPING
Year: 2014
Reference: Hum Brain Mapp. 2014 Dec;35(12):5799-814. doi: 10.1002/hbm.22586. Epub 2014 Jul 18.
Impact factor:
Publication type: Paper in international publication
Authors: Abdel-Aziz, Khaled; Arevalo, Maria J; Barkhof, Frederik; Bisecco, A; Ciccarelli, Olga; Comi, G; Damjanovic, D; Enzinger, Christian; Fazekas, Franz; Filippi, Massimo et al.
DOI: 10.1002/hbm.22586

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

PMID: 25520955
Journal: Neurology(R) neuroimmunology & neuroinflammation
Year: 2014
Reference: Neurol Neuroimmunol Neuroinflamm. 2014 Dec 11;1(4):e47. doi: 10.1212/NXI.0000000000000047. eCollection 2014 Dec.
Impact factor:
Publication type: Letter or abstract
Authors: Alvarez-Cermeno, Jose Carlos; Ara, Jose Ramon; Arroyo, Rafael; Brassat, David; Chan, Andrew; Comabella, Manuel; de la Hera, Belen; Fernandez, Oscar; Fissolo, Nicolas; Horga, Alejandro et al.
DOI: 10.1212/NXI.0000000000000047

Validation of semaphorin 7A and ala-beta-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis.

PMID: 25406498
Journal: Journal of Neuroinflammation
Year: 2014
Reference: J Neuroinflammation. 2014 Nov 13;11(1):181. doi: 10.1186/s12974-014-0181-8.
Impact factor:
Publication type: Paper in international publication
Authors: Alvarez-Cermeno, Jose Carlos; Borras, Eva; Canto, Ester; Chiva, Cristina; Comabella, Manuel; Montalban, Xavier; Rovira, Alex; Sabido, Eduard; Tintore, Mar; Villar, Luisa Maria et al.
DOI: 10.1186/s12974-014-0181-8

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.

PMID: 24029546
Journal: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Year: 2014
Reference: J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):851-8. doi: 10.1136/jnnp-2013-306132. Epub 2013 Sep 12.
Impact factor:
Publication type: Clinical Trials
Authors: AbouZeid, N; Absinta, M; AIpatov; Aladro, Y; Amelina, O; Amigo Jorrin, MdC; Anderson, G; Arroyo, R; Arroyo, R; Ayotte, C et al.
DOI: 10.1136/jnnp-2013-306132

Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease.

PMID: 23689404
Journal: ARQUIVOS DE NEURO-PSIQUIATRIA
Year: 2013
Reference: Arq Neuropsiquiatr. 2013 May;71(5):275-9.
Impact factor:
Publication type: Paper in international publication
Authors: Bichuetti, Denis Bernardi; Gabbai, Alberto Alain; Oliveira, Enedina Maria Lobato de; Souza, Nilton Amorin de; Tintore, Mar et al.
DOI:

MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis.

PMID: 23739915
Journal: BRAIN
Year: 2013
Reference: Brain. 2013 Jun;136(Pt 6):1778-82. doi: 10.1093/brain/awt101.
Impact factor:
Publication type: Paper in international publication
Authors: Akkad, Denis A; Aktas, Orhan; Alcina, Antonio; Alloza, Iraide; Antiguedad, Alfredo; Arroyo, Rafa; Ban, Maria; Bertram, Lars; Blaschke, Paul; Booth, David et al.
DOI: 10.1093/brain/awt101

Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls.

PMID: 23731539
Journal: AMERICAN JOURNAL OF HUMAN GENETICS
Year: 2013
Reference: Am J Hum Genet. 2013 Jun 6;92(6):854-65. doi: 10.1016/j.ajhg.2013.04.019. Epub 2013 May 23.
Impact factor:
Publication type: Paper in international publication
Authors: Ban, Maria; Baranzini, Sergio E; Barizzone, Nadia; Bergamaschi, Laura; Booth, David; Buck, Dorothea; Cavalla, Paola; Celius, Elisabeth G; Comabella, Manuel; Comi, Giancarlo et al.
DOI: 10.1016/j.ajhg.2013.04.019

Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases.

PMID: 23643683
Journal: NEUROLOGIA
Year: 2013
Reference: Neurologia. 2013 Jul-Aug;28(6):375-8. doi: 10.1016/j.nrl.2013.01.009. Epub 2013 May 3.
Impact factor:
Publication type: Review in national publication
Authors: Arbizu, T; de Andres, C; Fernandez, O; Garcia-Merino, A; Montalban, X; Oreja-Guevara, C; Rodriguez-Antiguedad, A et al.
DOI: 10.1016/j.nrl.2013.01.009

Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS.

PMID: 23278653
Journal: ACTA NEUROLOGICA SCANDINAVICA
Year: 2012
Reference: Acta Neurol Scand Suppl. 2012;(195):24-30. doi: 10.1111/ane.12024.
Impact factor:
Publication type: Paper in international publication
Authors: Buckow, K; Clanet, M; Clavelou, P; Confavreux, C; Ebers, G; Ellenberger, D; Eskic, D; Flachenecker, P; Friede, T; Fuge, J et al.
DOI: 10.1111/ane.12024

Spanish consensus on the use of natalizumab (Tysabri((R))) - 2011.

PMID: 22078648
Journal: NEUROLOGIA
Year: 2012
Reference: Neurologia. 2012 Sep;27(7):432-41. Epub 2011 Nov 9.
Impact factor:
Publication type: Paper in national publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1016/j.nrl.2011.09.008

Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.

PMID: 22183938
Journal: Multiple Sclerosis Journal
Year: 2012
Reference: Mult Scler. 2012 Jul;18(7):966-73. doi: 10.1177/1352458511432327. Epub 2011 Dec 19.
Impact factor:
Publication type: Paper in international publication
Authors: Dotan, N; Edan, G; Fire, E; Freedman, M S; Hartung, H-P; Kappos, L; Lanius, V; Metzig, C; Miller, D H; Montalban, X et al.
DOI: 10.1177/1352458511432327

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

PMID: 22992072
Journal: NEW ENGLAND JOURNAL OF MEDICINE
Year: 2012
Reference: N Engl J Med. 2012 Sep 20;367(12):1087-97.
Impact factor:
Publication type: Paper in international publication
Authors: Al Khedr, Abdullatif; Alfaro-Vidal, Teresa; Angnstwurm, Klemens; Antel, Jack; Antsov, Katrin; Apperson, Michelle; Applebee, Angela; Arjundas, Deepak; Arroyo, Rafael; Asher, Stephen et al.
DOI: 10.1056/NEJMoa1206328

Bilateral third nerve palsy with pupil involvement as the first manifestation of multiple sclerosis.

PMID: 22086433
Journal: REVISTA DE NEUROLOGIA
Year: 2011
Reference: Rev Neurol. 2011 Dec 1;53(11):703-704.
Impact factor:
Publication type: Paper in national publication
Authors: ; ; ; ; ; et al.
DOI:

Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis: Five-Year Clinical Trial Follow-up.

PMID: 22084124
Journal: ARCHIVES OF NEUROLOGY
Year: 2011
Reference: Arch Neurol. 2011 Nov;68(11):1421-7.
Impact factor:
Publication type: Paper in international publication
Authors: Aymerich, Francesc Xavier; Brieva, Luis; Calle, David; Comabella, Manuel; Galan, Ingrid; Montalban, Xavier; Nos, Carlos; Perkal, Hector; Rio, Jordi; Rovira, Alex et al.
DOI: 10.1001/archneurol.2011.241

[Spanish multi-centre observational study of the first attacks suggestive of multiple sclerosis: the PREM cohort].

PMID: 22052172
Journal: REVISTA DE NEUROLOGIA
Year: 2011
Reference: Rev Neurol. 2011 Nov 16;53(10):577-83.
Impact factor:
Publication type: Paper in national publication
Authors: Arroyo-Gonzalez, R; Aymerich, X; Bonaventura, I; de Andres, C; En Nombre Del Grupo de Investigadores Del Estudio ; Escartin, A; Escudero-Torrella, J; Farres, J; Lacruz, F; Marco-Igual, M et al.
DOI:

Role of tumour necrosis factor (TNF)-alpha and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis.

PMID: 22059991
Journal: CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Year: 2011
Reference: Clin Exp Immunol. 2011 Dec;166(3):338-45. doi: 10.1111/j.1365-2249.2011.04484.x.
Impact factor:
Publication type: Review in international publication
Authors: Caminero, A; Comabella, M; Montalban, X et al.
DOI: 10.1111/j.1365-2249.2011.04484.x

IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.

PMID: 20555355
Journal: GENES AND IMMUNITY
Year: 2010
Reference: Genes Immun. 2010 Jul;11(5):397-405. Epub 2010 Jun 17.
Impact factor:
Publication type: Paper in international publication
Authors: Alfredsson, L; Aubin, C; Barcellos, L F; Beecham, G; Bergamaschi, L; Bergamaschi, R; Bernardinelli, L; Boneschi, F M; Booth, D R; Brynedal, B et al.
DOI: 10.1038/gene.2010.28

Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement?

PMID: 20724066
Journal: CLINICAL NEUROLOGY AND NEUROSURGERY
Year: 2010
Reference: Clin Neurol Neurosurg. 2010 Dec;112(10):870-5. Epub 2010 Aug 19.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; et al.
DOI: 10.1016/j.clineuro.2010.07.014

Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study).

PMID: 20383518
Journal: JOURNAL OF NEUROLOGY
Year: 2010
Reference: J Neurol. 2010 Sep;257(9):1500-7. Epub 2010 Apr 10.
Impact factor:
Publication type: Paper in international publication
Authors: Arbizu, T; Arbizu, Txomin; Arroyo, R; Arroyo, Rafael; Ayuso, Guillermo Izquierdo; Bosca, I; Bosca, Isabel; Cermeno, Jose Carlos Alvarez; de las Heras, Virginia; de Ramon, E et al.
DOI: 10.1007/s00415-010-5560-1

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

PMID: 20236661
Journal: JOURNAL OF THE NEUROLOGICAL SCIENCES
Year: 2010
Reference: J Neurol Sci. 2010 May 15;292(1-2):28-35. Epub 2010 Mar 16.
Impact factor:
Publication type: Paper in international publication
Authors: Abramsky, O; Achiron, A; Achtnichts, L; Adbelhak, T; Adler, S; Ahmed, A; Allen, N; Alonso, A; Altintas, A; Anagnostou, P et al.
DOI: 10.1016/j.jns.2010.02.012

New options for early treatment of multiple sclerosis.

PMID: 19200870
Journal: JOURNAL OF THE NEUROLOGICAL SCIENCES
Year: 2009
Reference: J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11.
Impact factor:
Publication type: Paper in international publication
Authors: Tintore, Mar et al.
DOI: 10.1016/S0022-510X(09)70004-8

Plasma levels of 15d-PGJ are not altered in multiple sclerosis.

PMID: 19538219
Journal: EUROPEAN JOURNAL OF NEUROLOGY
Year: 2009
Reference: Eur J Neurol. 2009 Nov;16(11):1197-201.
Impact factor:
Publication type: Paper in international publication
Authors: Comabella, M; Fernandez, M; Julia, E; Lizasoain, I; Montalban, X; Moro, M A; Pradillo, J M; Rio, J; Sastre-Garriga, J et al.
DOI: 10.1111/j.1468-1331.2009.02696.x

MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.

PMID: 19433744
Journal: NEUROLOGY
Year: 2009
Reference: Neurology. 2009 May 12;72(19):1693-701.
Impact factor:
Publication type: Review in international publication
Authors: Barkhof, F; Calabrese, M; De Stefano, N; Fazekas, F; Filippi, M; Miller, D H; Montalban, X; Polman, C; Rocca, M A; Rovaris, M et al.
DOI: 10.1212/WNL.0b013e3181a55feb

Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis.

PMID: 19135155
Journal: NEUROIMAGE
Year: 2009
Reference: Neuroimage. 2009 Apr 1;45(2):500-11.
Impact factor:
Publication type: Paper in international publication
Authors: Agosta, F; Barkhof, F; Beckmann, C; Ciccarelli, O; De Stefano, N; Enzinger, C; Fazekas, F; Filippi, M; Friston, K; Gass, A et al.
DOI: 10.1016/j.neuroimage.2008.12.006

Blog

News

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Rates

Simoa HD1 equipment

We are seeking healthy volunteers for a study to find biomarkers of multiple sclerosis

We are looking for 100 healthy volunteers aged 18 or over to participate in a project where the usefulness of biomarkers in serum will be evaluated to predict the prognosis of the disease and the response to treatments.

More information